{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010091","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.734257+00:00","generated_at":"2026-05-16T10:57:40.475548+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lexeo Therapeutics reports positive interim Phase 1/2 clinical data for LX2020 in PKP2-ACM","bullets":["LX2020 generally well tolerated in 10 participants; no clinically significant complement activation observed","Mean PKP2 protein expression increased 93% in low-dose (n=2) and 162% in high-dose cohorts (n=5) by western blot","Non-sustained ventricular tachycardia reduced 22% (mean) in high-dose cohort (n=5); PVCs improved 14%","4 of 5 high-dose participants reported improvement on the PGIC patient-reported outcome scale","HEROIC-PKP2 enrollment completed Q4 2025; 12-month data for all high-dose participants expected Q4 2026"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010091","json":"https://secwatch.observer/filing/0001193125-26-010091.json","markdown":"https://secwatch.observer/filing/0001193125-26-010091.md","text":"https://secwatch.observer/filing/0001193125-26-010091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526010091/0001193125-26-010091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526010091/lxeo-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T10:57:40.475548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}